Zelnorm's Return: US FDA Panel Hands Down Split Decision On Constipation Drug's Target Population

Seven advisory committee members said the treatment for irritable bowel syndrome with constipation should be labeled for females at low cardiovascular risk; three panelists, including two cardiologists, supported a narrower indication limited to low CV risk patients who also suffer from severe symptoms.